Trial Profile
A Randomized, Double-blind, Four Period Cross-over Comparison of the Effect of Two Doses Lavoltidine, Esomeprazole, and Placebo on 24 Hour Gastric pH and Frequency of Heartburn in Symptomatic GERD Subjects Without Esophageal Erosions
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2023
Price :
$35
*
At a glance
- Drugs Esomeprazole (Primary) ; Lavoltidine (Primary) ; Ranitidine (Primary)
- Indications Gastro-oesophageal reflux
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 15 Oct 2008 Actual start date changed from Apr 2006 to May 2006 as reported by Clinicaltrials.gov
- 12 Oct 2008 Trial phase changed from I to II as reported by ClinicalTrials.gov.
- 22 Jun 2007 Status change from recruiting to completed